ImportantJNJ
Explain this story: Johnson & Johnson (JNJ) PT Raised to $278 at BofA Securities
BofA Securities analyst Jason M. Gerberry has raised the price target for Johnson & Johnson (NYSE: JNJ) to $278.00, an increase from the previous target of $263.00. This article, available exclusively to premium subscribers, reports on the analyst's updated rating for the pharmaceutical and medical device giant.
OtherStreetInsiderSector and industry: HealthcareDrug ManufacturersTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
BofA Securities analyst Jason M. Gerberry has raised the price target for Johnson & Johnson (NYSE: JNJ) to $278.00, an increase from the previous target of $263.00. This article, available exclusively to premium subscribers, reports on the analyst's updated rating for the pharmaceutical and medical device giant.
Article tone: Positive This describes the words the journalist used. It is not a prediction, and not advice.
Published Sep 29, 2026, 05:30 ET · on this site +1h 13m